Tenders are invited for Durvalumab (Genetical Recombination) (500 Mg/10 Ml/1 Vial) 280 Vials,And 44 Other Contracts Official in Charge of Disbursement of the Procuring Entity : Yuji Nishikawa, President, Asahikawa Medical University Classification of the Products to be Procured : 4 Nature and Quantity of the Products to be Purchased : A Durvalumab (Genetical Recombination) (500 Mg/10 Ml/1 Vial) 280 Vials B Palivizumab (Genetical Recombination) (100 Mg/1 Ml/1 Vial) 319 Vials C Goserelin Acetate (11.3 Mg/1 Syringe) 530 Syringes D Fulvestrant (250 Mg/5 Ml/2 Syringes/1 Case) 792 Cases E Risankizumab (Genetical Recombination) (75 Mg/0.83 Ml/1 Syringe) 302 Syringes F Ravulizumab (Genetical Recombination) (300 Mg/3 Ml/1 Vial) 129 Vials G Remdesivir (100 Mg/1 Vial) 512 Vials H Mepolizumab (Genetical Recombination) (100 Mg/1 Ml/1 Cartridge) 225 Cartridges I Botulinum Toxin Type a (100 Units/1 Vial) 307 Vials J Avalglucosidase Alfa (Genetical Recombination) (103 Mg/1 Vial) 260 Vials K Canakinumab (Genetical Recombination) (150 Mg/1 Vial) 218 Vials L Onasemnogene Abeparvovec (1 Set) 1 Set M Brolucizumab (Genetical Recombination) (19.8 Mg/0.165 Ml/1 Kit) 332 Kits N Nusinersen Sodium (12.63 Mg/5 Ml/1 Vial) 2 Vials O Ipilimumab (Genetical Recombination) (50 Mg/10 Ml/1 Vial) 137 Vials P Pomalidomide (4 Mg/7 Capsules/1 Case) 272 Cases Q Cetuximab (Genetical Recombination) (100 Mg/20 Ml/1 Vial) 1,301 Vials R Avelumab (Genetical Recombination) (200 Mg/10 Ml/1 Vial) 550 Vials S Daratumumab (Genetical Recombination)Vorhyaluronidase Alfa (Genetical Recombination) (1800 Mg/15 Ml/1 Vial30000 Units/15 Ml/1 Vial) 228 Vials T Pegfilgrastim (Genetical Recombination) (3.6 Mg/0.36 Ml/1 Syringe) 366 Syringes U Romiplostim (Genetical Recombination) (375 g/1 Vial) 312 Vials V Aflibercept (Genetical Recombination) (6.6 Mg/0.165 Ml/1 Kit) 868 Kits W Nivolumab (Genetical Recombination) (20 Mg/2 Ml/1 Vial) 792 Vials X Nivolumab (Genetical Recombination) (240 Mg/24 Ml/1 Vial) 868 Vials Y Dinutuximab (Genetical Recombination) (17.5 Mg/5 Ml/1 Vial) 24 Vials Z Paclitaxel (100 Mg/1 Vial) 829 Vials Aa Guselkumab (Genetical Recombination) (100 Mg/1 Ml/1 Syringe) 162 Syringes Ab Trastuzumab Deruxtecan (Genetical Recombination) (107 Mg/1 Vial) 355 Vials Ac Denosumab (Genetical Recombina- Tion) (120 Mg/1.7 Ml/1 Vial) 896 Vials Ad Bevacizumab (Genetical Recombination) (400 Mg/16 Ml/1 Vial) 994 Vials Ae Atezolizumab (Genetical Recombination) (1200 Mg/20 Ml/1 Vial) 278 Vials Af Pertuzumab (Genetical Recombination) (420 Mg/14 Ml/1 Vial) 388 Vials Ag Polatuzumab Vedotin (Genetical Recombination) (38 Mg/1 Vial) 444 Vials Ah Golimumab (Genetical Recombination) (50 Mg/0.5 Ml/1 Syringe) 300 Syringes Ai Ustekinumab (Genetical Recombination) (45 Mg/0.5 Ml/1 Syringe) 793 Syringes Aj Infliximab (Genetical Recombination) (100 Mg/1 Vial) 1,150 Vials Ak Ramucirumab (Genetical Recombination) (500 Mg/50 Ml/1 Vial) 247 Vials Al Ixekizumab (Genetical Recombination) (80 Mg/1 Ml/1 Kit) 189 Kits Am Human Haptoglobin (2000 Units/100 Ml/1 Vial) 358 Vials An Brentuximab Vedotin (Genetical Recombination) (55 Mg/1 Vial) 130 Vials Ao Vedolizumab (Genetical Recombination) (331.2 Mg/1 Vial) 88 Vials Ap Agalsidase Alfa (Genetical Recombination) (3.5 Mg/3.5 Ml/1 Vial) 66 Vials Aq Vosoritide (Genetical Recombination) (0.56 Mg/1 Vial) 364 Vials Ar Pembrolizumab (Genetical Recombination) (100 Mg/4 Ml/1 Vial) 1,766 Vials As Sugammadex Sodium (200 Mg/2 Ml/ 10 Vials/1 Case) 460 Cases Delivery Period : From 1, April, 2024 through 31, March, 2025 Delivery Place : Asahikawa Medical University Hospital Qualifications for Participating in the Tendering Procedures : Suppliers Eligible for Participating in the Proposed Tender are Those Who shall : A not Come under Article 4 and 5 of the Regulation Concerning the Contract for Asahikawa Medical University Furthermore, Minors, Person under Conservatorship or Person under Assistance that Obtained the Consent Necessary for Concluding a Contract may be Applicable under Cases of Special Reasons within the Said Clause, B have the Grade a, Grade B or Grade C Qualification during Fiscal 2024 in the Hokkaido Area in Sales of Products for Participating in Tenders by Single Qualification for Every Ministry and Agency, C Prove to have Obtained the First-Class License for Selling Drugs in Accordance with the Law on Securing Quality, Efficacy and Safety of Products including Pharmaceuticals and Medical Devices, D not be Currently under a Suspension of Business Order as Instructed by the President, The National University Corporation Asahikawa Medical University. Time Limit of Tender : 17 : 00 29, February, 2024 Contact Point for the Notice : Takashi Sunada, Procurement Section, Accounting Division, Asahikawa Medical University, 2-1-1-1 Midorigaokahigashi Asahikawa-Shi Hokkaido 078-8510 Japan, Tel 0166-69-3071 Please be Noted that if it is Indicated that Environmental Conditions Relating to the Procurement are Laid down in its Tender Documents. Tender Link : https://www.jetro.go.jp/en/database/procurement/national/articles/297359/2024010900970001.html
Dear Sir,
Warm Greetings from TenderDetail.com !!
We have received Tender Document request for the TDR No : 74861862
Tender Notice along with it's Attachments ( Tender Document / Scan Image of News Paper)
sent to your Email Address :.
Please check your email for Tender Document.